News Image

NASDAQ:EXEL, a growth stock which is not overvalued.

By Mill Chart

Last update: Nov 29, 2023

Our stock screener has singled out EXELIXIS INC (NASDAQ:EXEL) as an attractive growth opportunity. NASDAQ:EXEL is demonstrating remarkable growth potential while maintaining strong financial indicators, making it a reasonably priced option. We'll explore this further.

Deciphering NASDAQ:EXEL's Growth Rating

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:EXEL was assigned a score of 7 for growth:

  • The Revenue has grown by 8.31% in the past year. This is quite good.
  • EXEL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.91% yearly.
  • Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 33.60% on average per year.
  • EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.53% yearly.
  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

A Closer Look at Valuation for NASDAQ:EXEL

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:EXEL scores a 6 out of 10:

  • 93.98% of the companies in the same industry are more expensive than EXEL, based on the Price/Earnings ratio.
  • EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 96.32% of the companies in the same industry.
  • 93.65% of the companies in the same industry are more expensive than EXEL, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.82% of the companies listed in the same industry.
  • The excellent profitability rating of EXEL may justify a higher PE ratio.
  • A more expensive valuation may be justified as EXEL's earnings are expected to grow with 28.74% in the coming years.

ChartMill's Evaluation of Health

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:EXEL scores a 7 out of 10:

  • An Altman-Z score of 7.40 indicates that EXEL is not in any danger for bankruptcy at the moment.
  • EXEL has a Altman-Z score of 7.40. This is amongst the best in the industry. EXEL outperforms 86.29% of its industry peers.
  • EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • EXEL has a Current Ratio of 3.83. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
  • EXEL has a Quick Ratio of 3.76. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.

How do we evaluate the Profitability for NASDAQ:EXEL?

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:EXEL has earned a 8 out of 10:

  • With an excellent Return On Assets value of 3.09%, EXEL belongs to the best of the industry, outperforming 95.32% of the companies in the same industry.
  • The Return On Equity of EXEL (3.92%) is better than 94.82% of its industry peers.
  • EXEL's Return On Invested Capital of 1.23% is amongst the best of the industry. EXEL outperforms 94.31% of its industry peers.
  • The 3 year average ROIC (6.67%) for EXEL is well above the current ROIC(1.23%). The reason for the recent decline needs to be investigated.
  • EXEL has a better Profit Margin (5.18%) than 95.65% of its industry peers.
  • EXEL has a Operating Margin of 2.31%. This is amongst the best in the industry. EXEL outperforms 94.31% of its industry peers.
  • EXEL has a better Gross Margin (96.24%) than 95.82% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of EXEL

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

EXELIXIS INC

NASDAQ:EXEL (4/26/2024, 7:00:02 PM)

After market: 23.7 0 (0%)

23.7

+0.17 (+0.72%)

EXEL News

News Imagea day ago - InvestorPlaceThe Top 3 Biotech Stocks to Buy in April 2024

Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.

News Image4 days ago - ChartmillTechnical Signals Point to a Possible Breakout for EXELIXIS INC.

EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

News Image4 days ago - ChartmillNASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

News Image12 days ago - Exelixis, Inc.Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
News Imagea month ago - InvestorPlace3 Biotech Stocks to Buy on the Dip: March 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

News Imagea month ago - The Motley Fool4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.

News Image2 months ago - The Motley Fool2 Biotech Stocks to Buy Hand Over Fist in March

These stocks are worth buying in most months of the year.

News Image2 months ago - InvestorPlace3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success

With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.

News Image2 months ago - The Motley Fool4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

News Image2 months ago - Exelixis, Inc.Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
News Image2 months ago - Market News VideoFriday 2/23 Insider Buying Report: EXEL, HPP
News Image2 months ago - The Motley Fool2 Stocks Under $30 to Buy and Hold

You don't need to be a millionaire to get started. Investing on a budget can work, too.

EXEL Links
Follow us for more